

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

CHANGE OF COMPOSITION OF THE REMUNERATION COMMITTEE

The Board of Directors of China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Li Guohui (“**Mr. Li**”) has tendered his resignation as a member of the Remuneration Committee of the Company (the “**Remuneration Committee**”) with effect from 14 December 2016 due to other engagements with the Group which require more of his dedication. Mr. Li will remain as the Executive Director, Chief Financial Officer and Vice President of the Company.

Upon Mr. Li’s resignation as a member, the Remuneration Committee comprises one non-executive Director, being Mr. Chen Rong, and four independent non-executive Directors, being Mr. Tsang Hing Lun, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian.

Mr. Li confirmed that he has no disagreement with the other members of the Remuneration Committee and there is no other matter that needs to be brought to the attention of the shareholders of the Company.

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Executive Director

Hong Kong, 14 December 2016

As of the date of this announcement, the Board of Directors of the Company comprises Mr. Fu Yuning as chairman and non-executive Director, Mr. Wang Chuncheng, Mr. Song Qing and Mr. Li Guohui as executive Directors, Mr. Chen Rong, Mr. Yu Zhongliang, Mr. Wang Chenyang and Ms. Wang Jing as non-executive Directors, Mr. Tsang Hing Lun, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.